LabCorp 2006 Annual Report Download - page 5

Download and view the complete annual report

Please find page 5 of the 2006 LabCorp annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 56

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56

Coronary disease kills more Americans
than any other illness. That’s why one
of the most important steps toward
preserving good health is identifying
and reducing cardiovascular disease
risk factors. Conventional cholesterol
testing alone may not be sufficient –
more than half of patients who expe-
rienced a heart attack had “normal”
cholesterol test results.*
LabCorp has been a leader in
bringing to market more sensitive
assays, including the Vertical Auto
Profile (VAPTM) Cholesterol Test,
developed by Atherotech, and the
NMR Lipid Profile® Test, developed
by LipoScience, Inc. Both provide an
expanded analysis that measures
cholesterol subclasses within the blood
sample – indicators that can pinpoint
hidden heart disease risk. These more
sensitive tests provide additional infor-
mation that physicians use to diagnose
coronary disease earlier. An earlier
diagnosis can provide an opportunity
for physicians to aggressively treat
the disease and possibly to prevent
a catastrophic event such as a heart
attack from ever occurring.
*Source: Atherotech Web Site
CASE STUDY:
ADVANCED LIPID PROFILES
save lives
The availability of
just one new test has
the potential to save
millions of lives.
...........................................
....................................................